Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$3.36 USD
-0.12 (-3.31%)
Updated Apr 23, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/1/24 |
---|---|
Current Quarter | -0.39 |
EPS Last Quarter | -0.43 |
Last EPS Surprise | 8.51% |
ABR | 1.61 |
Earnings ESP
|
1.13% |
---|---|
Current Year | -1.69 |
Next Year | -1.69 |
EPS (TTM) | -2.01 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.04M | 0.04M | 0.15M | 0.15M |
# of Estimates | 4 | 4 | 5 | 3 |
High Estimate | 0.05M | 0.05M | 0.20M | 0.20M |
Low Estimate | 0.03M | 0.03M | 0.10M | 0.10M |
Year ago Sales | 0.05M | 0.04M | 0.16M | 0.15M |
Year over Year Growth Est. | -16.00% | 5.00% | -4.99% | 0.66% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.39 | -0.39 | -1.69 | -1.69 |
# of Estimates | 9 | 8 | 11 | 8 |
Most Recent Consensus | -0.41 | -0.41 | -1.67 | -1.79 |
High Estimate | -0.33 | -0.34 | -1.36 | -1.30 |
Low Estimate | -0.45 | -0.42 | -2.10 | -2.20 |
Year ago EPS | -0.68 | -0.53 | -2.01 | -1.69 |
Year over Year Growth Est. | 42.65% | 26.42% | 15.92% | 0.25% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 2 | 2 | 2 | 2 |
Up Last 60 Days | 4 | 4 | 6 | 3 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 1 | 2 | 3 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.39 | -0.39 | -1.69 | -1.69 |
7 Days Ago | -0.39 | -0.39 | -1.69 | -1.69 |
30 Days Ago | -0.41 | -0.41 | -1.73 | -1.74 |
60 Days Ago | -0.42 | -0.43 | -1.87 | -1.84 |
90 Days Ago | -0.44 | -0.44 | -1.89 | -1.80 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.39 | -0.40 | -1.60 | -1.66 |
Zacks Consensus Estimate | -0.39 | -0.39 | -1.69 | -1.69 |
Earnings ESP | 1.13% | -0.96% | 5.72% | 1.93% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.43 | -0.37 | -0.53 | -0.68 | NA |
Estimate | -0.47 | -0.53 | -0.59 | -0.63 | NA |
Difference | 0.04 | 0.16 | 0.06 | -0.05 | 0.05 |
Surprise | 8.51% | 30.19% | 10.17% | -7.94% | 10.23% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more